Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
TNYA Stock Chart & Stats
$1.33
-$0.05(-3.69%)
At close: 4:00 PM EST
$1.33
-$0.05(-3.69%)
Day’s Range― - ―
52-Week Range$0.36 - $2.35
Previous CloseN/A
Volume1.07M
Average Volume (3M)4.00M
Market Cap
$163.98M
Enterprise Value$219.84M
Total Cash (Recent Filing)$56.31M
Total Debt (Recent Filing)$11.53M
Price to Earnings (P/E)―
Beta2.80
Next Earnings
Mar 24, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding216,505,890
10 Day Avg. Volume2,873,734
30 Day Avg. Volume4,003,933
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.33
Enterprise Value/Market Cap1.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-55.68
Enterprise Value/Ebitda-2.53
Forecast
1Y Price Target
$9.14Price Target Upside587.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ReadoutsAnalysts view TN-401 and TN-201 clinical readouts as key catalysts because measurable reductions in arrhythmia burden and consistent biomarker improvements could materially de-risk the development programs.
Financial RunwayAnalysts point to a strengthened cash position as a catalyst, noting that sufficient runway can support continued clinical execution and regulatory interactions without immediate financing pressure.
Safety ProfileAnalysts highlight TN-401's tolerable safety profile with no dose-limiting toxicities or cardiotoxic events as a potential differentiator that could support broader clinical advancement if sustained in larger cohorts.
Bears Say
Clinical Hold OverhangClinical holds requiring standardized patient monitoring and immunosuppression protocols create regulatory overhang that could interrupt enrollment and delay trial progress.
Competitive Efficacy ComparisonAnalysts caution that observed protein expression increases appear smaller than some competitor reports, which could weaken competitive positioning if larger datasets do not show stronger responses.
Trial Variability And Data GapsSmall sample sizes, cases with no measurable expression, and patients lost to follow-up complicate interpretation of efficacy signals and raise uncertainty about program outcomes.
Tenaya Therapeutics News
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.36 and its highest was $2.35 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $163.98M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Mar 24, 2026 which is in 67 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.148 by $0.028.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 216,505,890 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.148. Following the earnings report the stock price went up 11.719%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenaya Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.14 (587.43% Upside)
$9.14 (587.43% Upside)
Hedge Fund Trend
Decreased
By 5.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.73%
12-Months-Change
Fundamentals
Return on Equity
-96.44%
Trailing 12-Months
Asset Growth
-25.32%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics (TNYA) is a biotechnology company focused on discovering, developing, and delivering curative therapies for heart disease. The company operates within the biopharmaceutical sector and is committed to advancing a pipeline of novel therapies aimed at addressing the underlying causes of various forms of heart disease through gene therapy, cellular regeneration, and precision medicine approaches.
TNYA Stock 12 Month Forecast
Average Price Target
$9.14
▲(587.43% Upside)
Technical Analysis
Galectin Therapeutics
―
Abeona Therapeutics
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Candel Therapeutics
―
Ownership Overview
54.76% Insiders
2.56% Mutual Funds
6.45% Other Institutional Investors
33.27% Public Companies and Individual Investors